ATAI ATAI Life Sciences N.V.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine.

$3.90  +0.06 (1.56%)
As of 05/26/2022 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Germany
Country of incorporation:  
IPO date:  10/16/2019
Outstanding shares:  160,732,785
Average volume:  880,297
Market cap:   $617,213,894
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BN6M8F1
Valuation   (See tab for details)
PE ratio:   -5.22
PB ratio:   1.66
PS ratio:   0.00
Return on equity:   -59.35%
Net income %:   -41,404.23%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy